A LUCKY lottery player has unknowingly been a millionaire for months but they must act soon to claim the money. The unknown ticket holder scooped a $1 million prize back in the summer. However, the money will soon be lost if the winner fails to stake their claim to it in a matter of days. The Cash 5 lottery ticket matched all five numbers in the draw on June 11 and was bought in Virginia . The winning slip has been traced back to a Wawa in Mechanicsville where it was bought on the day of the draw. But, with a 180-day deadline on claiming lottery wins, the player does not have long to find their ticket and head to the lottery office. read more on lottery wins The $1 million prize will expire after 5 pm on December 9. That gives the winner just over 24 hours to search their pockets and purses for the ticket. The winning numbers were: 1, 12, 19, 22, and 31. Lottery officials have urged the owner of the ticket to contact them immediately. Most read in Money If the deadline passes and the prize money goes unclaimed it will go to the state's Literary Fund. This money helps support local schools with renovations, upgrades, and new technology. The Virginia winner is not the only lottery player who needs to get their act in gear and claim their prize before it vanishes for good. A Powerball player from Ohio scooped a staggering windfall of $139 million. The draw was held months ago on July 3 when their ticket matched all five numbers and the Powerball. The winning ticket was bought at a Walmart store in Huber Heights, near Dayton. Millions dream of winning the lottery and finding fame and fortune. These are the biggest winners in US lottery history. Edwin Castro - $2.04 billion, Powerball, Nov. 8, 2022, in California. Theodorus Struyck - $1.765 billion, Powerball, Oct. 11, 2023, in California. Unknown winner - $1.602 billion, Mega Millions, Aug. 8, 2023, in Florida. Marvin and Mae Acosta from Los Angeles, California, John and Lisa Robinson from Munford, Tennessee, and Maureen Smith and David Kaltschmidt from Melbourne Beach, Florida - $1.586 billion, Powerball, Jan. 13, 2016. Unknown winner - $1.537 billion, Mega Millions, Oct. 23, 2018, from South Carolina. Unknown winner - he sued the mother of his child to keep his identity hidden - $1.348 billion, Mega Millions, Jan. 13, 2023, from Maine. Unknown winner - $1.337 billion, Mega Millions, July 29, 2022, from Illinois. Cheng and Duanpen Saephan , and Laiza Liem Chao - $1.326 billion, Powerball, April 7, 2024, from Oregon. Yanira Alvarez - $1.08 billion Powerball, July 19, 2023 in California. Wolverine FLL Lottery Club - $1.05 billion, Mega Millions, Jan. 22, 2021, from Michigan. Unknown winner - $842.4 million Powerball, Jan. 1, 2024, from Michigan. It marked the fifth time a Powerball jackpot was won this year. But, if the winner doesn't come forward to claim their prize in a few weeks, it will be lost. Read More on The US Sun Like the winner in Virginia, the Powerball player has 180 days from the draw date to collect their winnings. Meanwhile, other unsuspecting millionaires also need to claim their cash including a Mega Millions player who won $1 million.NATO head and Trump meet in Florida for talks on global security
Bengals keep playoff hopes alive, survive in OT vs. BroncosNoneCollege Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out
College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out
Russian President Vladimir Putin on Saturday signed a law that allows those who sign up to fight in Ukraine to write off unpaid debts worth almost $100,000, the government announced. The new legislation will be a strong motivation for some to join up, experts said, as Russia seeks new ways to recruit fighters for the nearly three-year conflict grinding through troops. The new legislation will allow those who sign a one-year contract to fight in Ukraine after December 1 to free themselves of existing bad debts. It also covers their spouses. The law concerns debts where a court order for collection was issued and enforcement proceedings began before December 1, 2024. The total amount of unpaid debt that can be covered is 10 million rubles, around $96,000 at current rates. Parliament approved the bill earlier this month. The legislation will largely concern younger Russians of fighting age, since those in their 30s and younger are most likely to have loans. Russia has extremely high interest rates for loans and many Russians have almost no cash savings, although the proportion of home owners is relatively high. "Previously (for those fighting) there was only provision for taking repayment holidays on loans," Sergei Krivenko of advocacy group Citizen Army Law told Vazhniye Istorii Telegram channel. The new legislation applies to those who are conscripted for national service and those mobilised for the so-called "special military operation", Krivenko said. Conscripts cannot be sent to the front line but can choose to sign a contract to join the professional army and be sent to fight in Ukraine. Russian authorities "are strengthening the motivation to sign a contract," political analyst Georgy Bovt wrote on Telegram. The legislation provides "another way to get rid of an unbearable burden of credit, at least for several hundred thousand people," Bovt wrote. Over 13 million Russians have three or more loans, according to a central bank report released last month covering the first two quarters. This was up 20 percent on the same period last year. The average amount owed by those with three or more loans is 1.4 million rubles ($13,400 at current rates). Many start with a bank loan and then apply for further loans from microfinance organisations. Russians serving on the front line are already paid far more than the national average. Ukraine also has legislation allowing those fighting to get preferential terms for loans and in some cases to write off debts. bur/twMan Utd cult hero Nani announces retirement with emotional video after tragic death of his father
In today’s digital age where data breaches and cyber threats loom large, the importance of secure offline storage can’t be overstated. As our lives become increasingly intertwined with technology, safeguarding our precious memories and sensitive documents has become paramount. This is where the Samsung T7 Portable SSD comes in. Currently available on Amazon as part of the Holiday Deals, the Samsung T7 Portable SSD with 2TB capacity is being offered at a price of $139, matching its Black Friday deal that saw the product fly off the shelves . This is a massive 48% discount from its list price of $269 (and even further if you consider its $399 launch price in 2020) which makes it a great option if you’re looking for high-performance external storage. See at Amazon Fast Transfer Speed The Samsung T7 SSD is delivering impressive specifications that set it apart from conventional external drives: At the heart of this device is its lightning-fast transfer speed which is capable of reaching up to 1,050 MB/s. This velocity is made possible by its USB 3.2 Gen 2 interface which allows for the rapid transfer of large files in mere seconds. This means you could potentially move a 4K movie file of around 50GB in less than a minute . The T7 utilizes Samsung’s advanced NAND flash memory technology and it is coupled with a USB 3.2 Gen 2 controller to achieve its impressive performance metrics. The drive supports the NVMe protocol which significantly reduces latency and allows for more efficient data transfer compared to older protocols. This combination of advanced hardware and optimized software results in faster transfer speeds and improved overall system responsiveness when working directly from the drive. In an era where data protection is crucial, this portable SSD offers peace of mind with its AES 256-bit hardware encryption : This military-grade encryption ensures that your data remains secure even if the drive falls into the wrong hands. Users can easily set up password protection through Samsung’s intuitive software which is compatible with Windows, macOS and Android operating systems. The T7’s robust build quality further enhances its reliability, featuring a sturdy metal enclosure that can withstand drops of up to 2 meters , protecting your data from physical shocks and everyday wear and tear. The practicality of the Samsung T7 extends beyond its performance and security features. Weighing just 58 grams and measuring a mere 85 x 57 x 8.0 mm, this ultra-portable drive can slip into a pocket or bag which makes it the perfect companion for on-the-go professionals, students or travelers. Its compatibility is impressive as it works with a wide range of devices including PCs, Macs, Android devices, and gaming consoles like the PlayStation 5 and Xbox Series X|S. See at AmazonTranscript: Frank McCourt on "Face the Nation with Margaret Brennan," Dec. 8, 2024Transportation Embedded PC Market Outlook and Future Projections for 2030 11-23-2024 11:02 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: Dhirtek Business Research and Consulting Transportation Embedded PC Market The transportation embedded pc market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the current state of the transportation embedded pc market but also forecasts its future trends. Scope and Purpose This report serves as an extensive resource, thoughtfully curated to deliver actionable intelligence to industry stakeholders. It covers critical elements such as market dynamics, competitive environments, growth opportunities, challenges, and regional differences. The insights provided go beyond mere descriptions, offering a valuable tool for stakeholders to refine their strategies and make informed choices in a competitive market. Request for Sample Report: https://www.dhirtekbusinessresearch.com/market-report/Transportation-Embedded-PC-Market/request-for-sample-report Comprehensive Market Analysis We are committed to providing a thorough analysis that explores every aspect of market growth, including shifts in consumer preferences and technological innovations driving demand for transportation embedded pc products. We also address the challenges faced by the industry, such as economic uncertainties and intense competition, offering insights to help stakeholders navigate these complexities. Key Players in the Transportation Embedded PC Market: Axiomtek Advantech Syslogic Cincoze Broadax Systems congatec Kontron VersaLogic MOXA NEXCOM IEI WINMATE KORENIX Strategic Guidance for the Future This report invites stakeholders to delve into a detailed examination of the competitive landscape. By profiling key players in the transportation embedded pc market and analyzing their strategies, we offer crucial insights to help industry participants make informed strategic decisions. Whether it's about outpacing competitors or learning from successful approaches, our analysis is designed to guide stakeholders toward success. Anticipated Insights Understanding the diverse segments within the transportation embedded pc market is critical to success. Our report breaks down segment sizes, potential growth trajectories, and key trends, offering actionable insights that allow stakeholders to develop targeted strategies and optimize resource allocation. The knowledge provided empowers stakeholders to navigate the complexities of the transportation embedded pc market with clarity and confidence. Balancing Market Forces and Strategic Impact This report delivers a comprehensive analysis of the factors shaping the transportation embedded pc market. By evaluating both the drivers of market growth and the obstacles that could impede it, stakeholders gain a holistic understanding of the market's dynamics. For manufacturers, this analysis helps align innovation efforts with consumer demands and regulatory trends, while investors and decision-makers gain a deeper understanding of economic risks and supply chain vulnerabilities, allowing them to make more informed strategic choices. Our goal is to provide stakeholders with the knowledge needed to confidently and successfully navigate the transportation embedded pc market. Competitive Landscape Our in-depth examination of the transportation embedded pc market's competitive landscape highlights key players, scrutinizing their strategies and impacts on the industry. By analyzing the approaches of major companies, stakeholders gain a valuable understanding of market dynamics and can leverage these insights to identify growth opportunities, innovate, and make informed strategic decisions. Market Segmentation The report begins with a detailed analysis of the unique characteristics defining each segment within the transportation embedded pc market. Segmentation can occur across various dimensions, including product types, customer demographics, or specific use cases. Understanding these differences allows stakeholders to tailor their strategies, products, and marketing efforts to meet the specific needs of each segment, enhancing competitive positioning and maximizing opportunities for success. Market Segments: Product Type: Dual Core Processor Quad Core Processor Others Application: Marine Railway Aerospace Others Market Size and Segment Growth Potential A crucial part of the report focuses on understanding the size and significance of each market segment. We provide quantitative data that illustrates the market share and contribution of each segment, enabling stakeholders to make informed decisions regarding resource allocation, strategic prioritization, and investment. This section offers insights into the growth potential of each segment, including factors driving future expansion, evolving consumer preferences, and technological adoption. Conclusion This report serves as a strategic guide for stakeholders in the transportation embedded pc market, offering comprehensive insights into market segmentation, competitive dynamics, and growth potential. By understanding the market's complexities and emerging opportunities, industry participants can make well-informed decisions that drive success and innovation in this rapidly evolving market. Other Reports Cerium Bromide Scintillator Market https://www.dhirtekbusinessresearch.com/market-report/Cerium-Bromide-Scintillator-Market Melamine Foam Block Market https://www.dhirtekbusinessresearch.com/market-report/Melamine-Foam-Block-Market High Energy Cast Booster Market https://www.dhirtekbusinessresearch.com/market-report/High-Energy-Cast-Booster-Market Offshore Photovoltaic Modules Market https://www.dhirtekbusinessresearch.com/market-report/Offshore-Photovoltaic-Modules-Market "Contact Us Dhirtek Business Research and Consulting Private Limited Contact No: +91 7580990088 Email Id: sales@dhirtekbusinessresearch.com" "About Us Dhirtek Business Research & Consulting Pvt Ltd is a global market research and consulting services provider headquartered in India. We offer our customers syndicated research reports, customized research reports, and consulting services. Our objective is to enable our clientele to achieve transformational progress and help them to make better strategic business decisions and enhance their global presence. We serve numerous companies worldwide, mobilizing our seasoned workforce to help companies shape their development through proper channeling and execution. We offer our services to large enterprises, start-ups, non-profit organizations, universities, and government agencies. The renowned institutions of various countries and Fortune 500 businesses use our market research services to understand the business environment at the global, regional, and country levels. Our market research reports offer thousands of statistical information and analysis of various industries at a granular level." This release was published on openPR.
New Chip King in Town? This AI Giant Is Giving Established Players a Run for Their MoneyWhy Ian Machado Garry Changed Shorts Mid-Fight at UFC 310
NSW Don't miss out on the headlines from NSW. Followed categories will be added to My News. Australian school students are among the most bullied in the world, with parents who have lost children to suicide warning they will not be the last unless all governments commit to urgent change. A survey by The Australian Council for Educational Research (ACER) found one in six students are bullied at school, a number that puts Australia ahead of comparative nations like the United States, England, New Zealand, Ireland and Canada. The most common form of bullying reported by children was being “made fun of”, while one in 10 students said they were deliberately “left out” by their peers and had “nasty rumours” spread about them. Country students reported being bullied more regularly than their city counterparts, while the ACER report also found kids at government schools experienced more bullying than those at Catholic and independent schools. The worrying statistics come after the release of the Charlotte’s Wish documentary by The Sunday Telegraph last week, in which parents across Australia laid bare the pain of losing a child to suicide after relentless bullying. Parents across Australia have shared their most personal pain, losing a child to suicide after relentless bullying, as part of the Sunday Telegraph’s Charlotte’s Wish documentary. One of the mums, Mel Graham, said she just “can’t comprehend” why more isn’t being done to stop bullies at school and online — and why her proposal for change eight years ago wasn’t implemented. “We know how to help these kids, we’ve been there. You can’t get this out of a textbook,” she said. Jessica Tolhurst, 14, took her own life before Christmas in 2015. Her mental health declined after constant online bullying. Picture: Supplied Her daughter, 14-year-old Jess Tolhurst, didn’t stand a chance, taking her own life in 2015, the day before her parents were taking her to the nearest Illawarra police station to secure an apprehended violence order against her abusers. “Bullying needs to be stamped out and schools need to be a safe place for all students and teachers,” Ms Graham said. “Consistent laws across states and territories should be designed to protect youths, schools and other organisations from abnormal violent harassing behaviour.” Jessica’s Law proposed to create a guiding set of principles to reduce and eliminate bullying and harassment before tragedy strikes. “Our calls have fallen on deaf ears and here we are again hearing about more children dying. It’s time to listen to us”. Mel Graham has been fighting against bullying in schools since her daughter Jess died eight years ago. Picture: Sam Ruttyn Amy “Dolly” Everett’s death in 2018 was one of the first times Australia stopped to talk about youth suicide, and her parents Kate and Tick have continued to push for change through Dolly’s Dream. Last week they put their support behind The Telegraph’s push for consistent national standards for bullying, which coincided with the launch of Charlotte’s Wish documentary. Earlier this month, as part of their own work with Dolly’s Dream, they asked their social media followers if they had experienced bullying at school. Of the more than 2200 respondents, 89 per cent said they had. The parents of Dolly Everett, who suicided after being relentlessly bullied, have thrown their support behind The Telegraph’s push for a consistent national standard to prevent bullying. Ms Everett said despite all the work they did learning about Australia’s bullying problem and trying to prevent another child losing their life, she still had days where she questioned why their daughter was targeted by bullies. “There won’t ever be a day where we look back and don’t think, ‘why us’, because we are an average rural family from the middle of nowhere in Australia,” she said. “Why (was she the child) that was picked on, or is that Australian culture and something that is systemic and built from our communities?” More Coverage Albanese vows to fulfil Charlotte’s Wish , Cydonee Mardon and Angira Bharadwaj We can’t lose another Charlotte: SA girl living same nightmare Cydonee Mardon Originally published as Nation of bullies: One in six school students fall victim Join the conversation Add your comment to this story To join the conversation, please log in. Don't have an account? Register Join the conversation, you are commenting as Logout More related stories News Gender equality ambassador spent $335k on airfares, hotels Since her appointment in December 2022, the ambassador has flown to 24 countries, including five times to the USA. Read more NSW Full list: Every NSW childcare centre rated The top rated and underperforming childcare centres across NSW have been revealed. Search and see the list and watch our exclusive videos. Read moreThe new, 12-team College Football Playoff brings with it a promise to be bigger, more exciting, more lucrative. Perfect or 100% fair? Well, nobody ever believed that. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week
New Chip King in Town? This AI Giant Is Giving Established Players a Run for Their Money
(PRNewsfoto/Johnson & Johnson) 100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . View original content to download multimedia: https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-302325575.html SOURCE Johnson & JohnsonMartirena opened the scoring in the 15th minute and Martinez added a goal five minutes later to give “La Academia” its first international title since 1988 when it won the Supercopa Sudamericana. “Maravilla” Martinez scored 10 goals in 13 matches and finished as the top scorer in the competition. Roger Martinez sealed the victory with a goal in the 90th. Kaio Jorge scored in the 52nd for Cruzeiro. AP soccer: https://apnews.com/hub/soccer
Biaxially Oriented Film Production Line Market Outlook and Future Projections for 2030 11-23-2024 10:59 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: Dhirtek Business Research and Consulting Biaxially Oriented Film Production Line Market The biaxially oriented film production line market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the current state of the biaxially oriented film production line market but also forecasts its future trends. Scope and Purpose This report serves as an extensive resource, thoughtfully curated to deliver actionable intelligence to industry stakeholders. It covers critical elements such as market dynamics, competitive environments, growth opportunities, challenges, and regional differences. The insights provided go beyond mere descriptions, offering a valuable tool for stakeholders to refine their strategies and make informed choices in a competitive market. Request for Sample Report: https://www.dhirtekbusinessresearch.com/market-report/Biaxially-Oriented-Film-Production-Line-Market/request-for-sample-report Comprehensive Market Analysis We are committed to providing a thorough analysis that explores every aspect of market growth, including shifts in consumer preferences and technological innovations driving demand for biaxially oriented film production line products. We also address the challenges faced by the industry, such as economic uncertainties and intense competition, offering insights to help stakeholders navigate these complexities. Key Players in the Biaxially Oriented Film Production Line Market: JSW Marshall and Williams Plastics Sumino Precision Machine Brückner Maschinenbau ARCHANTE GLESI Shandong Yongjian Machinery Mitsubishi Windmöller & Hölscher Dongsheng Intelligent Equipment Strategic Guidance for the Future This report invites stakeholders to delve into a detailed examination of the competitive landscape. By profiling key players in the biaxially oriented film production line market and analyzing their strategies, we offer crucial insights to help industry participants make informed strategic decisions. Whether it's about outpacing competitors or learning from successful approaches, our analysis is designed to guide stakeholders toward success. Anticipated Insights Understanding the diverse segments within the biaxially oriented film production line market is critical to success. Our report breaks down segment sizes, potential growth trajectories, and key trends, offering actionable insights that allow stakeholders to develop targeted strategies and optimize resource allocation. The knowledge provided empowers stakeholders to navigate the complexities of the biaxially oriented film production line market with clarity and confidence. Balancing Market Forces and Strategic Impact This report delivers a comprehensive analysis of the factors shaping the biaxially oriented film production line market. By evaluating both the drivers of market growth and the obstacles that could impede it, stakeholders gain a holistic understanding of the market's dynamics. For manufacturers, this analysis helps align innovation efforts with consumer demands and regulatory trends, while investors and decision-makers gain a deeper understanding of economic risks and supply chain vulnerabilities, allowing them to make more informed strategic choices. Our goal is to provide stakeholders with the knowledge needed to confidently and successfully navigate the biaxially oriented film production line market. Competitive Landscape Our in-depth examination of the biaxially oriented film production line market's competitive landscape highlights key players, scrutinizing their strategies and impacts on the industry. By analyzing the approaches of major companies, stakeholders gain a valuable understanding of market dynamics and can leverage these insights to identify growth opportunities, innovate, and make informed strategic decisions. Market Segmentation The report begins with a detailed analysis of the unique characteristics defining each segment within the biaxially oriented film production line market. Segmentation can occur across various dimensions, including product types, customer demographics, or specific use cases. Understanding these differences allows stakeholders to tailor their strategies, products, and marketing efforts to meet the specific needs of each segment, enhancing competitive positioning and maximizing opportunities for success. Market Segments: Product Type: High Speed Biaxially Oriented Film Production Line Low Speed Biaxially Oriented Film Production Line Application: Packaging Film Optical Film Industrial Film Others Market Size and Segment Growth Potential A crucial part of the report focuses on understanding the size and significance of each market segment. We provide quantitative data that illustrates the market share and contribution of each segment, enabling stakeholders to make informed decisions regarding resource allocation, strategic prioritization, and investment. This section offers insights into the growth potential of each segment, including factors driving future expansion, evolving consumer preferences, and technological adoption. Conclusion This report serves as a strategic guide for stakeholders in the biaxially oriented film production line market, offering comprehensive insights into market segmentation, competitive dynamics, and growth potential. By understanding the market's complexities and emerging opportunities, industry participants can make well-informed decisions that drive success and innovation in this rapidly evolving market. Other Reports Rail Guided Shuttle Market https://www.dhirtekbusinessresearch.com/market-report/Rail-Guided-Shuttle-Market Carbon Fiber Woven Fabric Market https://www.dhirtekbusinessresearch.com/market-report/Carbon-Fiber-Woven-Fabric-Market Pediatric Endotracheal Tube Market https://www.dhirtekbusinessresearch.com/market-report/Pediatric-Endotracheal-Tube-Market Crawler Robots Market https://www.dhirtekbusinessresearch.com/market-report/Crawler-Robots-Market "Contact Us Dhirtek Business Research and Consulting Private Limited Contact No: +91 7580990088 Email Id: sales@dhirtekbusinessresearch.com" "About Us Dhirtek Business Research & Consulting Pvt Ltd is a global market research and consulting services provider headquartered in India. We offer our customers syndicated research reports, customized research reports, and consulting services. Our objective is to enable our clientele to achieve transformational progress and help them to make better strategic business decisions and enhance their global presence. We serve numerous companies worldwide, mobilizing our seasoned workforce to help companies shape their development through proper channeling and execution. We offer our services to large enterprises, start-ups, non-profit organizations, universities, and government agencies. The renowned institutions of various countries and Fortune 500 businesses use our market research services to understand the business environment at the global, regional, and country levels. Our market research reports offer thousands of statistical information and analysis of various industries at a granular level." This release was published on openPR.
Owaisi asks party workers not to lose heart with Maha poll resultsWalmart ( NYSE:WMT – Free Report ) had its target price increased by KeyCorp from $88.00 to $96.00 in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has an overweight rating on the retailer’s stock. A number of other equities research analysts have also weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Walmart from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Truist Financial upgraded Walmart from a “hold” rating to a “buy” rating and upped their target price for the stock from $76.00 to $89.00 in a report on Tuesday, September 24th. Melius Research initiated coverage on Walmart in a research note on Monday, September 23rd. They issued a “buy” rating and a $95.00 target price for the company. DA Davidson upped their price target on Walmart from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Guggenheim raised their price objective on Walmart from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 28th. Two research analysts have rated the stock with a hold rating, twenty-nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.88. Read Our Latest Analysis on Walmart Walmart Stock Up 2.3 % Walmart ( NYSE:WMT – Get Free Report ) last posted its earnings results on Tuesday, November 19th. The retailer reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.05. Walmart had a return on equity of 21.78% and a net margin of 2.92%. The firm had revenue of $169.59 billion for the quarter, compared to analysts’ expectations of $167.69 billion. During the same period in the previous year, the firm earned $0.51 earnings per share. The business’s revenue was up 5.5% compared to the same quarter last year. Sell-side analysts forecast that Walmart will post 2.47 earnings per share for the current year. Insiders Place Their Bets In other news, EVP John D. Rainey sold 3,000 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $82.12, for a total value of $246,360.00. Following the completion of the sale, the executive vice president now directly owns 378,165 shares in the company, valued at $31,054,909.80. This represents a 0.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link . Also, CEO C Douglas Mcmillon sold 29,124 shares of Walmart stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $80.64, for a total value of $2,348,559.36. Following the transaction, the chief executive officer now owns 3,873,053 shares in the company, valued at $312,322,993.92. This trade represents a 0.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last ninety days, insiders have sold 12,337,337 shares of company stock worth $958,823,647. Company insiders own 45.58% of the company’s stock. Institutional Investors Weigh In On Walmart Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Summit Financial Wealth Advisors LLC increased its stake in shares of Walmart by 0.5% in the third quarter. Summit Financial Wealth Advisors LLC now owns 23,720 shares of the retailer’s stock worth $1,915,000 after purchasing an additional 118 shares in the last quarter. Providence Wealth Advisors LLC boosted its holdings in Walmart by 0.3% in the 3rd quarter. Providence Wealth Advisors LLC now owns 43,549 shares of the retailer’s stock worth $3,591,000 after buying an additional 122 shares during the period. 3Chopt Investment Partners LLC increased its stake in Walmart by 0.4% in the 3rd quarter. 3Chopt Investment Partners LLC now owns 32,633 shares of the retailer’s stock worth $2,635,000 after buying an additional 124 shares in the last quarter. CAP Partners LLC raised its holdings in Walmart by 2.1% during the third quarter. CAP Partners LLC now owns 6,054 shares of the retailer’s stock valued at $489,000 after acquiring an additional 125 shares during the period. Finally, Investment Advisory Group LLC lifted its position in shares of Walmart by 2.1% in the third quarter. Investment Advisory Group LLC now owns 6,182 shares of the retailer’s stock valued at $499,000 after acquiring an additional 126 shares in the last quarter. 26.76% of the stock is owned by hedge funds and other institutional investors. Walmart Company Profile ( Get Free Report ) Walmart Inc engages in the operation of retail, wholesale, other units, and eCommerce worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam's Club. It operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, and discount stores under Walmart and Walmart Neighborhood Market brands; membership-only warehouse clubs; ecommerce websites, such as walmart.com.mx, walmart.ca, flipkart.com, PhonePe and other sites; and mobile commerce applications. Featured Articles Five stocks we like better than Walmart How to Invest in the Best Canadian Stocks Tesla Investors Continue to Profit From the Trump Trade Bank Stocks – Best Bank Stocks to Invest In MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally Profitably Trade Stocks at 52-Week Highs Netflix Ventures Into Live Sports, Driving Stock Momentum Receive News & Ratings for Walmart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walmart and related companies with MarketBeat.com's FREE daily email newsletter .